Pfizer launches Phase 2b trial of multi-antigen Staphylococcus aureus vaccine

Pfizer launches Phase 2b multi-antigen Staphylococcus aureus vaccine | Courtesy of

Pfizer, Inc. said Tuesday it has enrolled its first patient in the company’s Phase 2b clinical trial for its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (P-06290510) for adults having elective spinal fusion surgery.

The goal of the study, called STRIVE for STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy, is to determine the efficacy and safety of the vaccine, which will show whether the vaccine effectively prevents postoperative invasive S. aureus infections for patients who have had elective spinal surgery.

Health professionals have noted that surgical site infections (SSIs) have become a growing health concern. SSIs involving S. aureus make up approximately 20 percent of the SSIs within the U.S. Yearly treatment costs for SSIs amount to $12.3 billion in the U.S., and many of the patients who contract SSIs are antibiotic sensitive or antibiotic resistant.

“We are pleased to take this important next step in the development of our S. aureus vaccine,” Pfizer Senior Vice President and Chief Scientific Officer of Vaccine Research and Development Kathrin Jansen said. “To date, there is no licensed vaccine available to prevent invasive S. aureus disease. We believe results from this study, if positive, will bring us closer to a potential preventive measure for this challenging disease that is associated with considerable morbidity and mortality.”

Organizations in this story

Pfizer 235 E 42nd St New York, NY 10017-5703

Get notified the next time we write about Pfizer!